Floatz logo

Dapagliflozin

Blood Pressure

University of Campinas, BrazilSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Blood Pressure cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
Yuhan Corporation
Phase 4BBB
AMLODIPINE
Yuhan Corporation
Phase 4BBB
Tomato Fruit Extract
Beata Krasinska
Phase 4BB
LABETALOL
ProMedica Health System
Phase 3BB
Phentermine
VIVUS LLC
Phase 4BB

View all 44 →

Same molecule, other indications

Dapagliflozin is also rated in:

type 2 diabetes mellitusDormant
BBB
Indicative ·
78 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
77 / 100
View asset →
arteriosclerosis disorderDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →